Five things for pharma marketers to know: Thursday, January 18, 2018
Senate committee votes in favor of Azar as new HHS head; FDA and DoD launch breakthrough designation program; Walmart offers free opioid disposal solution
Opioids
Five things for pharma marketers to know: Thursday, January 11, 2018
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
Five things for pharma marketers to know: Friday, January 5, 2018
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
Five things for pharma marketers to know: Thursday, December 28, 2017
Study: male docs earn more than female peers; new Michigan law tackles opioid crisis; study: some docs billed Medicare for most expensive patient visit type
Five things for pharma marketers to know: Friday, December 1, 2017
FDA approves first Apple Watch health accessory; medical charity shared data with pharma donors; FDA approves opioid-addiction treatment
Five things for pharma marketers to know: Thursday, November 30, 2017
FDA releases information on Exondys 51; Sanofi’s dengue vaccine faces new restrictions; Kellyanne Conway named opioid czar
Limits on pharma payments to doctors back on policy menu
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
Five things for pharma marketers to know: Tuesday, November 7, 2017
Senator investigates Alkermes’ opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide
CDC tells opioid addiction stories with message: ‘It only takes a little to lose a lot’
The CDC has launched the first wave of its awareness campaign about prescription opioids.
Five things for pharma marketers to know: Tuesday, October 31, 2017
Pfizer Q3 revenue driven by Prevnar sales; President Trump’s opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
